Navigation Links
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:3/13/2008

obesity. Arena's broad pipeline of novel compounds targeting G protein-coupled receptors, an important class of validated drug targets, includes compounds being evaluated independently and with its partners, Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, the results of clinical trials or preclinical studies may not be predictive of future results, Arena's ability to partner lorcaserin, APD125, APD791 or other of its compounds or programs, the timing, success and cost of Arena's research, out-licensing endeavors and clinical trials, Arena's ability to obtain additional financing, Arena's ability to obtain and defend its patents, the timing and receipt of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward- looking statements represent Arena'
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... DuPont Tate & Lyle Bio ... it has appointed Skidmore Sales & Distributing ... Essex Grain Products and Processor’s ... in the food and beverage markets. The ... mid-western states: Alabama, Arkansas, Connecticut, Delaware, Florida, ...
(Date:9/11/2014)... LONDON , Sept. 11, 2014 ... (CRT), the charity,s development and commercialisation arm, have reached ... biotechnology company in the emerging field of regenerative ... AST-VAC2 into clinical trials in subjects with non-small ... tenth treatment to enter Cancer Research UK,s Clinical ...
(Date:9/11/2014)... The Stem Cell Institute, located in ... umbilical cord stem cell therapy on Saturday, September 20, 2014 ... Resort from 1:00 pm to 4:00 pm. , Stem ... – “Umbilical Cord Stem Cell Clinical Trials for MS and ... founder of the Stem Cell Institute and Medistem Panama Inc. ...
(Date:9/10/2014)... Brunswick, New Jersey (PRWEB) September 11, 2014 ... will host its annual Innovations in Dermatological Sciences ... meeting will focus on how the university, industry ... dermatological research into clinical use. , This conference ... had experience with cross-sector collaboration, to share their ...
Breaking Biology Technology:DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 2DuPont Tate & Lyle Bio Products Appoints Skidmore Sales as Distributor for Zemea® USP 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 2Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 3Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 4Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 5Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 6Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 7Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner To Trial Immunotherapy Vaccine For Lung Cancer 8Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 2Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 3Stem Cell Institute Public Seminar on Adult Stem Cell Therapy Clinical Trials in San Antonio, Texas September 20th, 2014 4Innovations in Dermatological Sciences 2014 2Innovations in Dermatological Sciences 2014 3
... Ocean energy company, BioPower Systems (BPS), today announced ... Hon. Michael O,Brien MP, has awarded the company conditional ... Pilot Demonstration Program. The funding will be ... company,s 250kW bioWAVE ocean wave energy system at a ...
... RSB Spine announced today that it received a revised ... an interbody implant with integrated fixation and an anterior ... for stand-alone interbody devices with integrated fixation.   The new ... new code for cervical interbody devices is OVE.   In ...
... 30, 2011  Nutra Pharma Corporation (OTCBB: NPHC), a biotechnology ... Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced ... publishing a mechanism study on the use of Alpha-Cobratoxin, ... pain. The paper was co-authored by Paul Reid, PhD ...
Cached Biology Technology:BioPower Systems Awarded $5 Million from Victorian Government 2BioPower Systems Awarded $5 Million from Victorian Government 3FDA Establishes New Product Codes for Interbody Devices With Integrated Fixation 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 2Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain 3
(Date:9/12/2014)... an active role in the destruction and remodelling ... being an ,innocent bystander, as previously thought. , ... Lawler, Dr Ben Croker and colleagues from the ... while investigating the role of the protein SOCS3 ... was published in the journal Arthritis and ...
(Date:9/12/2014)... coccidiosis is a serious parasitic infection of young ... to diarrhoea and reduced nutritional intake. As the ... can result in increased mortality, the disease is ... farms., "The developing immune system of neonatal piglets ... the parasites. For this reason, an infection shortly ...
(Date:9/11/2014)... with autism often show a reduced frequency of ... in repetitive solitary behaviors. Autism has also been ... structure involved in processing emotions. Now Caltech researchers ... amygdala that control whether the animal engages in ... may have implications for understanding neural circuit dysfunctions ...
Breaking Biology News(10 mins):No innocent bystander: Cartilage contributes to arthritis 2Piglet health 2Piglet health 3Tipping the balance of behavior 2Tipping the balance of behavior 3
... the late 1800s, a flurry of fossil speculation across the ... Bone Wars. Drawn into the spectacle were two scientists ... acclaimed as the Father of Texas Geology, and naturalist Jacob ... Hill and Boll had supporting roles in the Bone ...
... to the amount of unhealthy foods they eat, but can ... new study in the Journal of Consumer Research . ... willpower and desire, consumers can,t rely entirely on willpower to ... will make them lose interest in food. One way is ...
... side-effects caused by the anti-parasitic drug quinine in the treatment ... The research, carried out by Nottingham scientists on the University,s ... in our levels of the amino acid, tryptophan, has a ... appears that the lower our levels of tryptophan the more ...
Cached Biology News:Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 2Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 3Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 4Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 5Eat dessert first? It might help you control your diet 2Diet could combat adverse side-effects of quinine 2Diet could combat adverse side-effects of quinine 3
Goat anti-VAV2 Class: Antibody Product Group: Miscellaneous Antibody...
Indoleamine 2,3-dioxygenase [IDO]...
Request Info...
Pancreatic Cell Cryopreservation Medium (2X) is intended for the cryopreservation of LT2 Immortalized Pancreatic Mesenchymal Cells (SCR013) and VIT1 Primary Pancreatic Mesenchymal Cells (SCR014)....
Biology Products: